{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:24:38Z","timestamp":1793813078193,"version":"4.6.1"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>IgA nephropathy recurrence after kidney transplantation is a common complication, which is most often detected histologically. Recurrence after transplant affects long-term graft survival, with prognosis being worse with increasing levels of proteinuria, a higher histological activity, and concurrent rejection. Treatment in kidney transplant patients is similar to that in native kidneys: using renin\u2013angiotensin\u2013aldosterone system (RAAS) blockade agents, steroids, and increased immunosuppression. Iptacopan, an inhibitor of alternative complement pathway factor B, has demonstrated reduction in proteinuria and complement activity in native IgAN. However, it has not been studied in recurrent IgAN after kidney transplant. We present a case of recurrent IgAN refractory to conventional therapy with clinical and histological improvement after treatment with iptacopan. A 39-year-old male patient underwent a deceased donor kidney transplantation. A 3-month biopsy showed features of recurrent IgAN in the transplanted kidney. Following treatment for rejection, subsequent biopsies demonstrated active IgAN with worsening proteinuria, which was treated with rituximab, cyclophosphamide, and steroids. Despite these interventions, there was no improvement in IgAN or proteinuria. At 40 months post-transplant, the patient was started on iptacopan, after which a follow-up biopsy showed resolution of active IgA activity. The patient has tolerated iptacopan well and has not had any adverse events or serious infections.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1803607","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:46:05Z","timestamp":1777632365000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Recurrence of IgA nephropathy in a kidney transplant patient successfully treated with iptacopan\u2014a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Jay","family":"Pandav","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basheer","family":"Kummangal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"De Mattos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Stack","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoha","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Andeen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderlene","family":"Kung","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Olyaei","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehzad","family":"Rehman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02802-x","article-title":"Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study","volume":"23","author":"J\u00e4ger","year":"2022","journal-title":"BMC Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00910121","article-title":"Recurrence of IgA nephropathy after kidney transplantation in adults","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1277017","article-title":"Risk factors and outcomes of IgA nephropathy recurrence after kidney transplantation: a systematic review and meta-analysis","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03667.x","article-title":"Steroids and recurrent IgA nephropathy after kidney transplantation","volume":"11","author":"Clayton","year":"2011","journal-title":"Am J Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000453081","article-title":"Predicting post-transplant recurrence of IgA nephropathy: the importance of crescents","volume":"45","author":"Avasare","year":"2017","journal-title":"Am J Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs472","article-title":"The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival","volume":"28","author":"Moroni","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000519834","article-title":"Clinical predictors and prognosis of recurrent IgA nephropathy in the kidney allograft","volume":"2","author":"Kavanagh","year":"2022","journal-title":"Glomerul Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.202425vyres0","article-title":"SGLT2 inhibitors reduce the rate of decline in the estimated glomerular filtration rate of kidney transplant patients with recurrent or De Novo glomerulonephritis: TH-PO742","volume":"35","author":"Kwon","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00882-9","article-title":"Complement activation Medjeral-Thomas NR, Cook HT, Pickering MC. Complement activation in IgA nephropathy","volume":"43","author":"Medjeral-Thomas","year":"2021","journal-title":"Semin Immunopathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2025.101189","article-title":"Early experience with iptacopan for recurrent IgA nephropathy after kidney transplantation","volume":"8","author":"Al Jurdi","year":"2025","journal-title":"Kidney Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2025.08.015","article-title":"Targeting the alternative complement pathway by iptacopan abrogates C3 and strongly reduces C5b-9 deposition within glomeruli in IgA nephropathy recurrence after kidney transplantation","volume":"25","author":"Sanna","year":"2025","journal-title":"Am J Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1803607\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:46:06Z","timestamp":1777632366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1803607\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2026.1803607"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1803607","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1803607"}}